Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Fate Therapeutics, Inc. - Common Stock
(NQ:
FATE
)
1.060
-0.080 (-7.02%)
Streaming Delayed Price
Updated: 12:16 PM EST, Dec 1, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Fate Therapeutics, Inc. - Common Stock
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Despite Durability Questions, BMO Upgraded This Natural-Killer Cell Therapy Oncology Stock
↗
July 12, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 12, 2022
↗
July 12, 2022
Upgrades
Via
Benzinga
Expert Ratings for Fate Therapeutics
↗
July 11, 2022
Within the last quarter, Fate Therapeutics (NASDAQ:FATE) has observed the following analyst ratings:
Via
Benzinga
Recap: Fate Therapeutics Q1 Earnings
↗
May 04, 2022
Fate Therapeutics (NASDAQ:FATE) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Via
Benzinga
Earnings Scheduled For February 28, 2022
↗
February 28, 2022
Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 11, 2022
↗
July 11, 2022
Upgrades
Via
Benzinga
7 Small-Cap Stocks to Buy in July 2022
↗
July 04, 2022
These are the best small-cap stocks to buy for July 2022. ARCH, AVUV, CEIX, COUR, DVAX, FATE, and TENB can make great investments.
Via
InvestorPlace
Will Another Enlivex Innovation Break The Glass Ceiling For Solid Tumor Treatments?
↗
June 14, 2022
Cell therapy — the use of stem cells and various engineered immune cells to target difficult-to-treat diseases like cancer and autoimmune conditions — has arguably been one of the big breakthroughs in...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 3, 2022
↗
June 03, 2022
Via
Benzinga
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
↗
May 04, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
What 4 Analyst Ratings Have To Say About Fate Therapeutics
↗
March 04, 2022
Within the last quarter, Fate Therapeutics (NASDAQ:FATE) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total...
Via
Benzinga
Fate Therapeutics: Q4 Earnings Insights
↗
February 28, 2022
Fate Therapeutics (NASDAQ:FATE) reported its Q4 earnings results on Monday, February 28, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings...
Via
Benzinga
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
↗
February 27, 2022
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first...
Via
Benzinga
Fate Therapeutics's Earnings: A Preview
↗
February 25, 2022
Fate Therapeutics (NASDAQ:FATE) is set to give its latest quarterly earnings report on Monday, 2022-02-28. Here's what investors need to know before the announcement. Analysts...
Via
Benzinga
Earnings Outlook For Fate Therapeutics
↗
February 25, 2022
Fate Therapeutics (NASDAQ:FATE) is set to give its latest quarterly earnings report on Monday, 2022-02-28. Here's what investors need to know before the announcement. Analysts...
Via
Benzinga
2 Natural-Killer Cell Therapy Oncology Companies Investors Should Watch
↗
February 08, 2022
Natural-killer cell therapy is one of the most recent paradigms in cancer treatment, and two prominent companies working on this new technology are Fate Therapeutics Inc (NASDAQ: FATE) and Century...
Via
Benzinga
Benzinga Asks: Which ARK Fund Would You Rather Buy And Hold For 5 Years?
↗
January 14, 2022
One of the best-known and well-covered ETF companies over the past five years has been ARK Invest, led by Cathie Wood. With t...
Via
Benzinga
Here's How Much $100 Invested In Fate Therapeutics 5 Years Ago Would Be Worth Today
↗
January 05, 2022
Fate Therapeutics (NASDAQ:FATE) has outperformed the market over the past 5 years by 64.83% on an annualized basis. Buying $100 In FATE: 5 years ago, an investor could have...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 15, 2021
↗
December 15, 2021
Upgrades B of A Securities upgraded the previous rating for ONE Gas Inc (NYSE:
Via
Benzinga
10 Biggest Price Target Changes For Wednesday
↗
December 15, 2021
Barclays boosted the price target on Sysco Corporation (NYSE:
Via
Benzinga
The Daily Biotech Pulse: Mesoblast, Novartis Sever COVID-19 Treatment Partnerships, Sigilon To Reduce Workforce, ASH Presentations Move Stocks
↗
December 14, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Vaccitech To Buy Avidea For $40M Vaccitech plc (NASDAQ: VACC) announced that...
Via
Benzinga
Fate Therapeutics Showcases Interim Data From FT596 Cell Program In Lymphoma
↗
December 14, 2021
Fate Therapeutics Inc (NASDAQ: FATE) showcased interim Phase 1 data from its FT596 program for patients with relapsed / refractory B-cell lymphoma (BCL) at the...
Via
Benzinga
Hedge Funds Are Selling Vontier Corporation
↗
December 11, 2021
Vontier Corporation investors should pay attention to a decrease in activity from the world’s largest hedge funds recently. Vontier Corporation was in 31 hedge funds’ portfolios at the end of...
Via
Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For December 7, 2021
↗
December 07, 2021
Upgrades For CarMax Inc (NYSE:
Via
Benzinga
Cathie Wood Likes Fate Therapeutics, Should You?
↗
December 01, 2021
The biotech has an interesting pipeline, but it's all early stage products.
Via
The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For November 9, 2021
↗
November 09, 2021
Upgrades JP Morgan upgraded the previous rating for New Relic Inc (NYSE:
Via
Benzinga
Fate Therapeutics, inc (FATE) Q3 2021 Earnings Call Transcript
↗
November 05, 2021
FATE earnings call for the period ending October 31, 2021.
Via
The Motley Fool
Topics
Earnings
3 Biotech Stocks to Watch Now
↗
October 12, 2021
Biotech companies develop new medicines, vaccines, or medical devices. They use advanced technologies and medical science to do so. Most biotech stocks trade at low prices and...
Via
Benzinga
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
↗
November 04, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &...
Via
Benzinga
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
↗
October 31, 2021
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...
Via
Benzinga
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
